Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF-2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma

被引：0
|
作者：
Zhu, Yihao [1 ]
Li, Yajian [1 ]
Li, Xuwen [1 ]
Yu, Yuan [2 ]
Zhang, Lingpu [3 ,4 ]
Zhang, Hanchen [3 ,4 ]
Chen, Can [5 ]
Chen, Dong [1 ]
Wang, Mingshuai [1 ]
Xing, Nianzeng [1 ]
Yang, Feiya [1 ]
Wasilijiang, Wahafu [1 ,6 ]
Ye, Xiongjun [1 ]
机构：
[1] Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing,100021, China
[2] Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Zhejiang,310022, China
[3] Beijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing,100190, China
[4] University of Chinese Academy of Sciences, Beijing,100049, China
[5] Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Guizhou,563000, China
[6] Department of Urology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Shanxi,030013, China
来源：
Advanced Healthcare Materials | 2024年 / 13卷 / 32期
关键词：
Tumors;
D O I：
10.1002/adhm.202402973
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation
    Chan, Kok Hoe
    Li, Ningjing
    Lador, Ran
    Amsbaugh, Mark
    Gonzalez, Anneliese
    Cen, Putao
    JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2024, 12
  • [32] Cross talk between oxidative stress and hypoxia via thioredoxin and HIF-2α drives metastasis of hepatocellular carcinoma
    Cao, Man-Qing
    You, A-Bin
    Cui, Wei
    Zhang, Su
    Guo, Zhi-Gui
    Chen, Lu
    Zhu, Xiao-Dong
    Zhang, Wei
    Zhu, Xiao-Lin
    Guo, Hua
    Deng, Da-Jun
    Sun, Hui-Chuan
    Zhang, Ti
    FASEB JOURNAL, 2020, 34 (04): : 5892 - 5905
  • [33] Combined inhibition of autophagy with mTOR inhibitor to enhance cell death in renal cell carcinoma.
    Chen, Hua
    Potts, Kyle
    Murray, Allan
    Hitt, Mary
    Moore, Ron
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [34] MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis
    Fengqi Yan
    Qinhao Wang
    Mingyuan Xia
    Yi Ru
    Wei Hu
    Guang Yan
    Xin Xiong
    Mei Zhang
    Jiancai Wang
    Qi Li
    Bo Zhang
    He Wang
    Wei Lin
    Guojun Wu
    Xia Li
    Cancer Biology & Medicine, 2022, 19 (06) : 818 - 835
  • [35] Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 patients with clear cell renal cell carcinoma.
    Doshi, Sahil D.
    Kuo, Fengshen
    Knezevic, Andrea
    Kotecha, Ritesh R.
    Motzer, Robert J.
    Hakimi, A. Ari
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 445 - 445
  • [36] TBC1D5 reverses the capability of HIF-2α in tumor progression and lipid metabolism in clear cell renal cell carcinoma by regulating the autophagy
    Huang, Yu
    Xiong, Zhiyong
    Wang, Jianjun
    Gao, Yafen
    Cao, Qi
    Wang, Decai
    Shi, Jian
    Chen, Zhixian
    Yang, Xiong
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [37] Phase 2 study of the oral hypoxia-inducible factor 2[alpha] (HIF-2[alpha]) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
    Choueiri, Toni K.
    Bauer, Todd Michael
    McDermott, David F.
    Arrowsmith, Edward
    Roy, Ananya
    Perini, Rodolfo F.
    Vickery, Donna
    Tykodi, Scott S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [38] MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis
    Yan, Fengqi
    Wang, Qinhao
    Xia, Mingyuan
    Ru, Yi
    Hu, Wei
    Yan, Guang
    Xiong, Xin
    Zhang, Mei
    Wang, Jiancai
    Li, Qi
    Zhang, Bo
    Wang, He
    Lin, Wei
    Wu, Guojun
    Li, Xia
    CANCER BIOLOGY & MEDICINE, 2022, 19 (06) : 818 - 835
  • [39] Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC).
    Choueiri, Toni K.
    Albiges, Laurence
    Fan, Li
    Perini, Rodolfo F.
    Zojwalla, Naseem J.
    Powles, Thomas
    Rini, Brian, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients
    Emerling, Brooke M.
    Benes, Cyril H.
    Poulogiannis, George
    Bell, Eric L.
    Courtney, Kevin
    Liu, Hui
    Choo-Wing, Rayman
    Bellinger, Gary
    Tsukazawa, Kazumi S.
    Brown, Victoria
    Signoretti, Sabina
    Soltoff, Stephen P.
    Cantley, Lewis C.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (09) : 3483 - 3488
12345